glp 1 medications australia Supporting patients through GLP-1 agonist cessation effects Ozempic, Wegovy, Saxenda and Mounjaro

Robin Zon called the findings a promising hypothesis for #cancerprevention in people with obesity

The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course

Give us a call!

No side effects like the nausea or headache

Yes GLP3 is the informal name for retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors.

But certain limitations persist.